# YN001-004 in Patients With Coronary Atherosclerosis in Australia

> **NCT06700720** · PHASE2 · RECRUITING · sponsor: **Beijing Inno Medicine Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Coronary Artery Disease
- Coronary Atherosclerotic Disease

## Interventions

- **DRUG:** Dose 1 YN001
- **DRUG:** Dose 2 YN001
- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT06700720
- **Lead sponsor:** Beijing Inno Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06700720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06700720, "YN001-004 in Patients With Coronary Atherosclerosis in Australia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06700720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*